Ludwig Enterprises Inc, operates as a biotech and healthcare holding company. The company is headquartered in Pompano Beach, Florida. The company went IPO on 2007-12-11. Its proprietary mRNA genomic technology has the potential of screening for genetic biomarkers for inflammatory-driven diseases, including, but not limited to, heart disease, diabetes, preeclampsia, cancer and long COVID. The firm employs a non-invasive cheek swab test to collect mRNA samples. Its initial product candidate is the Revealia Breast test, a non-invasive cheek swab assay designed to detect molecular signatures in mRNA expression associated with the presence of breast cancer. Its technology platform integrates three key components: non-invasive sample collection, genomic analysis, and machine learning-based interpretation.
LUDG stock price ended at $0.06 on 星期五, after dropping 14.29%
On the latest trading day Jan 23, 2026, the stock price of LUDG fell by 14.29%, dropping from $0.06 to $0.06. During the session, the stock saw a volatility of 0.00%, with prices oscillating between a daily low of $0.06 and a high of $0.06. On the latest trading day, the trading volume for LUDG decreased by 7.0K shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 10.0K shares were traded, with a market value of approximately $19.0M.